The next diagnostic step is obtaining blood for detection of acetylcholine receptor antibodies which are present in about 85 to 90 percent of patients with myasthenia gravis. The final diagnostic step ...

Medically reviewed by Smita Patel, DO The Tensilon test was discontinued in the U.S. in 2018. It was performed to help ...

Amgen AMGN reported the latest data from the phase III MINT study that evaluated the rare disease drug Uplizna (inebilizumab) ...

So people with myasthenia gravis present obviously with muscle weakness ... The other electrodiagnostic tests we do is called single fiber EMG or measurement of jitter. And this is a test ...

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent ...

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular ...